Session 14 Diagnostic Improvement of Renal Ultrasonography in Humans after IV Injection of Perflenapent Emulsion; Jean-Michel Correas, MD, Lina Menassa, MD, Olivier H616non, MD Arnaud M@jean, MD, Jean-Christophe Boyer, MD Marie-France Mamzer, MD, Jean-Franqois Moreau, MD The work in progress in US contrast media remains fo- cused on the production of microbubbles injected intrave- nously and trespassing the pulmonary barrier to reach the systemic circulation, then producing preexisting signal en- hancemem or even genuine self-created signals (1,2). Be- sides the field of manufactured encapsulated micro- bubbles, which has been the most open to varied experi- ments until the '80s, the concept of phased-shift introduced by Quay (3) is attractive because of the theo- retic lack of preoperative management of the compound available at the liquid phase. Perflenapent emulsion is the first generation of preparation. The demonstration of the USCA clinical utility using dodecafluoropentane (DDFP) has not been reported in renal vascular and parenchymal disorders. Our purpose was to evaluate Pertlenapent emul- sion from the results of a phase IlI clinical trial including 19 patients using contrast-enhanced renal ultrasonography. Nineteen patients (11 women, eight men) were enrolled in this phase III study, carried out in accordance to the Declaration of Helsinki. Mean age was 46.2 years +_ 17.7, and mean weight was 64 kg _+ 12. Perflenapent emulsion was administered at 0.05 mL/kg as a bolus injection fol- lowing hypobaric activation in a 20-gange catheter in- serted in an antecubital vein. The compound was flushed with 10 mL of saline. All examinations were performed on a Toshiba SSA-270 unit (Toshiba Medical Systems Europe, Delft, The Netherlands) with a 3.75-MHz transducer and recorded on an S-VHS PAL videotape. Color Doppler stud- ies included velocity and power encoding. The pulse repeti- tion frequency was adapted to the velocity expected within the investigated vessels. The color gain was optimized dur- ing baseline study and reduced in case of blooming artifact. Pulsed Doppler was used to authenticate blood flow and to assess blood velocity. Patients were referred by their physicians for a contrast- enhanced study after an inconclusive ultrasound and Dop- pler examination. They were included only after an incon- clusive baseline study according to two experienced radi- ologists (J.M.C., O.H.), who evaluated each case separately. All patients underwent a complete physical examination with a review of their medical history. Vital signs (includ- ing blood pressure, cardiac and respiratory rates) were monitored prior to and after administration of the USCA. Safety evaluation also included laboratory tests of glucose, serum electrolytes, urea, creatinine, cholesterol, liver-en- zyme plasma levels, and blood-cell count, before and after the procedure. Definite diagnoses were obtained by multi- modality imaging techniques, such as computed tomogra- phy (CT), contrast-enhanced magnetic resonance imaging (MRI), angiography, and/or surgery. RESULTS Acad Radio11998; 5(suppl 1):$185-$188 From the Departments of Radiology (J,M,C., L,M., O.H., J,C.B,, J,F.M,), Urology (A.M.), and Renal Transplantation (JrF.M,), Necker Hospital, 149 rue de S+vres, 75015 Paris, France, Supported by a grant from Sonus Pharmaceuticals (European Phase III FDA approval), Ad- dress reprint requests to J.M.C, ©AUR, 1998 Renal Masses (n = 9) The study population encompassed nine renal masses, including seven renal cell carcinomas, one cystic carci- noma, and one complicated calyceal diverticulum. After administration of Perflenapent emulsion, intratumoral color Doppler signal intensity increased significantly in all cases $185